# ARQT catalysts: Arcutis Biotherapeutics, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/arqt/catalysts

> Arcutis Biotherapeutics, Inc. (ARQT) has 3 upcoming catalysts. The next is the ZORYVE (roflumilast) PDUFA date, February 23, 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for ARQT?

Arcutis Biotherapeutics, Inc. (ARQT) has 3 upcoming catalysts. The next is the ZORYVE (roflumilast) PDUFA date, February 23, 2027. Press release filed with the SEC (EX-99): "•The FDA has set a target action date of February 23, 2027, for the supplemental New Drug Application to expand the indication for ZORYVE cream 0.05% for mild to moderate atopic dermatitis to infants aged 3 to 24 months." [Calendar and source filings](https://sec-api.dev/companies/arqt/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001787306-26-000056, https://www.sec.gov/Archives/edgar/data/1787306/000178730626000056/pressreleaseex991q32026.htm (retrieved 2026-11-12). Last confirmed 2026-11-04. Cite: https://sec-api.dev/companies/arqt/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Arcutis Biotherapeutics, Inc. |
| Ticker | ARQT (Nasdaq) |
| SEC CIK | 1787306 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/arqt |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| July 29, 2022 | [ZORYVE (roflumilast) FDA approval](https://sec-api.dev/pdufa/roflumilast) | ARQT |  | completed, approved | "NDA215985 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20220729, review_priority STANDARD; sponsor_name ARCUTIS; product ZORYVE (ROFLUMILAST)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215985%22)) |
| Sep 2022 | [Arcutis Biotherapeutics, Inc. topline data readout](https://sec-api.dev/companies/arqt/catalysts) | ARQT |  | completed, positive | "We announced positive topline data from our Phase 3 scalp and body psoriasis trial in September 2022, and we submitted an sNDA to the FDA for a label expansion to include scalp and body psoriasis in adults and adolescents ages 12 and over, which was accepted by the FDA with a PDUFA target action date in May 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1787306/000178730625000029/arqt-20241231.htm)) |
| Sep 2022 | [ZORYVE (roflumilast) topline data readout](https://sec-api.dev/pdufa/roflumilast) | ARQT |  | completed, positive | "We announced positive Phase 3 topline data in September 2022, with ZORYVE foam showing rapid disease clearance and significant reduction in itch." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1787306/000178730625000092/arqt-20250331.htm)) |
| Sep 2022 | [Arcutis Biotherapeutics, Inc. topline data readout](https://sec-api.dev/companies/arqt/catalysts) | ARQT |  | completed, positive | "We announced positive topline data in September 2022, and have submitted our sNDA with a PDUFA in May 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1787306/000178730625000029/arqt-20241231.htm)) |
| Sep 2023 | [Arcutis Biotherapeutics, Inc. topline data readout](https://sec-api.dev/companies/arqt/catalysts) | ARQT |  | completed, positive | "In September 2023, we announced positive topline data from INTEGUMENT-PED Trial." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1787306/000178730626000018/arqt-20251231.htm)) |
| October 5, 2023 | [ZORYVE (roflumilast) label expansion decision](https://sec-api.dev/pdufa/roflumilast) | ARQT | plaque psoriasis | completed, approved | "NDA215985 SUPPL-2 (Efficacy): submission_status AP, submission_status_date 20231005, review_priority STANDARD; sponsor_name ARCUTIS; product ZORYVE (ROFLUMILAST)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215985%22)) |
| December 15, 2023 | [ZORYVE (roflumilast) FDA approval](https://sec-api.dev/pdufa/roflumilast) | ARQT | seborrheic dermatitis in individuals aged 9 years and older, with no limitation | completed, approved | "NDA217242 ORIG-1 (Type 3 - New Dosage Form and Type 4 - New Combination): submission_status AP, submission_status_date 20231215, review_priority STANDARD; sponsor_name ARCUTIS; product ZORYVE (ROFLUMILAST)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA217242%22)) |
| Jul 2024 | [ZORYVE (roflumilast) FDA approval](https://sec-api.dev/pdufa/roflumilast) | ARQT |  | completed, approved | "In addition to the approval of ZORYVE cream 0.3% for plaque psoriasis and ZORYVE foam for seborrheic dermatitis and plaque psoriasis of the scalp and body, we also received FDA approval for and commercially launched ZORYVE (roflumilast) cream 0.15% (ZORYVE cream 0.15%) in July 2024 for the treatment of mild to moderate atopic dermatitis in adults and pediatric patients 6 years of age and older, with no limitation on location, body surface area treated, concomitant use, or duration of use specified in the approved labelling." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1787306/000178730625000144/arqt-20250930.htm)) |
| July 9, 2024 | [ZORYVE (roflumilast) label expansion decision](https://sec-api.dev/pdufa/roflumilast) | ARQT |  | completed, approved | "NDA215985 SUPPL-7 (Efficacy): submission_status AP, submission_status_date 20240709, review_priority STANDARD; sponsor_name ARCUTIS; product ZORYVE (ROFLUMILAST)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215985%22)) |
| Dec 2024 | [ZORYVE (roflumilast) NDA/BLA submission](https://sec-api.dev/pdufa/roflumilast) | ARQT |  | completed | "Based on the positive results from the INTEGUMENT-PED study, and given our recent approval of ZORYVE cream 0.15% for the treatment of mild to moderate atopic dermatitis in individuals 6 years of age or older, we submitted a supplemental new drug application (sNDA) for topical ZORYVE cream 0.05% for children 2 to 5 years of age in December 2024, which was accepted by the FDA with a Prescription Drug User Fee Act (PDUFA) target action date in October 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1787306/000178730625000124/arqt-20250630.htm)) |
| January 12, 2025 | [Arcutis Biotherapeutics, Inc. earnings report](https://sec-api.dev/companies/arqt/catalysts) | ARQT |  | completed | "Arcutis will report complete fourth quarter and full-year 2024 financial results and provide a business update on Tuesday, February 25, 2025 after the U.S. financial markets close." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1787306/000178730625000004/pressreleaseex991pre-earni.htm)) |
| February 25, 2025 | [Arcutis Biotherapeutics, Inc. earnings report](https://sec-api.dev/companies/arqt/catalysts) | ARQT |  | completed | "Arcutis Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1787306/000178730625000028/pressreleaseex991q42024.htm)) |
| May 6, 2025 | [Arcutis Biotherapeutics, Inc. earnings report](https://sec-api.dev/companies/arqt/catalysts) | ARQT |  | completed | "Arcutis Announces First Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1787306/000178730625000091/pressreleaseex991q12025.htm)) |
| May 22, 2025 | [ZORYVE (roflumilast) PDUFA date](https://sec-api.dev/pdufa/roflumilast) | ARQT |  | completed, approved | "•The Company submitted an sNDA for ZORYVE foam for scalp and body psoriasis to the FDA based on the positive results from the pivotal ARRECTOR Phase 3 trial and a Phase 2b trial, and has been assigned a PDUFA action date of May 22, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1787306/000178730625000091/pressreleaseex991q12025.htm)) |
| May 22, 2025 | [ZORYVE (roflumilast) label expansion decision](https://sec-api.dev/pdufa/roflumilast) | ARQT |  | completed, approved | "NDA217242 SUPPL-5 (Efficacy): submission_status AP, submission_status_date 20250522, review_priority STANDARD; sponsor_name ARCUTIS; product ZORYVE (ROFLUMILAST)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA217242%22)) |
| Jun 2025 | [ZORYVE (roflumilast) trial start](https://sec-api.dev/pdufa/roflumilast) | ARQT |  | completed | "In June 2025, we initiated INTEGUMENT-INFANT, a Phase 2 study to evaluate the safety and efficacy of investigational ZORYVE cream 0.05% in infants as young as 3 months to less than 2 years with atopic dermatitis, which potentially could serve as the basis for a further expansion of the indication for ZORYVE cream 0.05% to this group of patients." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1787306/000178730625000144/arqt-20250930.htm)) |
| August 6, 2025 | [Arcutis Biotherapeutics, Inc. earnings report](https://sec-api.dev/companies/arqt/catalysts) | ARQT |  | completed | "Arcutis Announces Second Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1787306/000178730625000122/pressreleaseex991q22025.htm)) |
| Sep 2025 | [ZORYVE (roflumilast) NDA/BLA submission](https://sec-api.dev/pdufa/roflumilast) | ARQT | plaque psoriasis in children down | completed | "In September 2025, we submitted a supplemental New Drug Application (sNDA) to FDA to expand the indication of ZORYVE cream 0.3% for the treatment of plaque psoriasis in children down to the age of 2." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1787306/000178730625000144/arqt-20250930.htm)) |
| October 4, 2025 | [ZORYVE (roflumilast) label expansion decision](https://sec-api.dev/pdufa/roflumilast) | ARQT |  | completed, approved | "NDA215985 SUPPL-12 (Efficacy): submission_status AP, submission_status_date 20251004, review_priority STANDARD; sponsor_name ARCUTIS; product ZORYVE (ROFLUMILAST)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215985%22)) |
| October 13, 2025 | [ZORYVE (roflumilast) PDUFA date](https://sec-api.dev/pdufa/roflumilast) | ARQT | atopic dermatitis in children ages 2 to 5 with an | completed, approved | "•The Company has been assigned a Prescription Drug User Fee Act (PDUFA) action date of October 13, 2025 for the supplemental New Drug Application (sNDA) for ZORYVE cream 0.05% for the treatment of atopic dermatitis in children ages 2 to 5 years old." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1787306/000178730625000122/pressreleaseex991q22025.htm)) |
| October 28, 2025 | [Arcutis Biotherapeutics, Inc. earnings report](https://sec-api.dev/companies/arqt/catalysts) | ARQT |  | completed | "Arcutis Outlines Strategy for Driving Sustainable Growth and Announces Third Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1787306/000178730625000142/pressreleaseex991q32025.htm)) |
| Nov 2025 | [ZORYVE (roflumilast) NDA/BLA acceptance](https://sec-api.dev/pdufa/roflumilast) | ARQT | plaque psoriasis in children down | completed | "In November 2025, our supplemental New Drug Application (sNDA) was accepted for filing by the FDA to potentially expand the indication of ZORYVE cream 0.3% for the treatment of plaque psoriasis in children down to the age of 2, with a Prescription Drug User Fee Act (PDUFA) target action date assigned for June 29, 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1787306/000178730626000040/arqt-20260331.htm)) |
| December 4, 2025 | [Arq-151 cream 0.05% primary completion](https://sec-api.dev/pdufa/arq-151-cream-0-05) | ARQT | Atopic Dermatitis (Eczema) | completed | "NCT06998056 (Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-12-04 (ACTUAL); Lead Sponsor Arcutis Biotherapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06998056)) |
| Q1 2026 | [ARQ-234 trial start](https://sec-api.dev/pdufa/arq-234) | ARQT |  | scheduled | "We submitted an Investigational New Drug application (IND) to the FDA in July 2025, and anticipate commencing a Phase 1 study of ARQ-234 in the first quarter of 2026." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1787306/000178730626000018/arqt-20251231.htm)) |
| Feb 2026 | [ZORYVE (roflumilast) topline data readout](https://sec-api.dev/pdufa/roflumilast) | ARQT |  | completed, positive | "•In February 2026, we announced positive topline data for INTEGUMENT-INFANT, a Phase 2 study evaluating the safety and efficacy of investigational ZORYVE cream 0.05% in infants as young as 3 months to less than 2 years of age with atopic dermatitis." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1787306/000178730626000057/arqt-20260930.htm)) |
| February 25, 2026 | [Arcutis Biotherapeutics, Inc. earnings report](https://sec-api.dev/companies/arqt/catalysts) | ARQT |  | completed | "Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1787306/000178730626000017/pressreleaseex991q42025.htm)) |
| Mar 2026 | [ARQ-234 trial start](https://sec-api.dev/pdufa/arq-234) | ARQT | moderate-to-severe atopic dermatitis | completed | "In March 2026, the Company initiated a Phase 1a/1b clinical trial of ARQ-234 for the treatment of moderate-to-severe atopic dermatitis." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1787306/000178730626000057/arqt-20260930.htm)) |
| Q2 2026 | [ZORYVE (roflumilast) NDA/BLA submission](https://sec-api.dev/pdufa/roflumilast) | ARQT |  | scheduled | "The Company plans to submit an sNDA for ZORYVE cream 0.05% for this age group in Q2 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1787306/000178730626000017/pressreleaseex991q42025.htm)) |
| June 29, 2026 | [ZORYVE (roflumilast) PDUFA date](https://sec-api.dev/pdufa/roflumilast) | ARQT | plaque psoriasis in children down | completed, approved | "•sNDA accepted for ZORYVE cream 0.3% for the treatment of plaque psoriasis down to 2 years of age with a Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1787306/000178730626000017/pressreleaseex991q42025.htm)) |
| June 29, 2026 | [ZORYVE (roflumilast) label expansion decision](https://sec-api.dev/pdufa/roflumilast) | ARQT | children with plaque psoriasis down | completed, approved | "NDA215985 SUPPL-15 (Efficacy): submission_status AP, submission_status_date 20260629, review_priority STANDARD; sponsor_name ARCUTIS; product ZORYVE (ROFLUMILAST)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215985%22)) |
| July 31, 2026 | [Arcutis Biotherapeutics, Inc. earnings report](https://sec-api.dev/companies/arqt/catalysts) | ARQT |  | completed | "Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1787306/000178730626000049/pressreleaseex991q22026.htm)) |
| Q4 2026 | [ZORYVE (roflumilast) topline data readout](https://sec-api.dev/pdufa/roflumilast) | ARQT | vitiligo with disclosure of topline results and decision | scheduled | "•Remains on track to disclose topline results from Phase 2 trial of ZORYVE foam 0.3% in individuals with vitiligo and decision on program advancement in Q4 of 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1787306/000178730626000056/pressreleaseex991q32026.htm)) |
| November 4, 2026 | [Arcutis Biotherapeutics, Inc. earnings report](https://sec-api.dev/companies/arqt/catalysts) | ARQT |  | completed | "Arcutis Announces Third Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1787306/000178730626000056/pressreleaseex991q32026.htm)) |
| February 23, 2027 | [ZORYVE (roflumilast) PDUFA date](https://sec-api.dev/pdufa/roflumilast) | ARQT | infants with atopic dermatitis down | scheduled | "•The FDA has set a target action date of February 23, 2027, for the supplemental New Drug Application to expand the indication for ZORYVE cream 0.05% for mild to moderate atopic dermatitis to infants aged 3 to 24 months." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1787306/000178730626000056/pressreleaseex991q32026.htm)) |
| Apr to Jul 2028 | [Roflumilast cream 0.3% topline data readout](https://sec-api.dev/pdufa/roflumilast-cream-0-3) | ARQT | Atopic Dermatitis; Atopic Dermatitis (AD); Atopic Dermatitis (Eczema) | scheduled | "NCT07916480 (Roflumilast Cream 0.3% for Moderate to Severe Atopic Dermatitis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-04-27 (ESTIMATED); Lead Sponsor Arcutis Biotherapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07916480)) |
| April 2028 | [Roflumilast cream 0.3% primary completion](https://sec-api.dev/pdufa/roflumilast-cream-0-3) | ARQT | Atopic Dermatitis; Atopic Dermatitis (AD); Atopic Dermatitis (Eczema) | scheduled | "NCT07916480 (Roflumilast Cream 0.3% for Moderate to Severe Atopic Dermatitis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-04-27 (ESTIMATED); Lead Sponsor Arcutis Biotherapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07916480)) |

## Drugs

- [Arq-151 cream 0.05%](https://sec-api.dev/pdufa/arq-151-cream-0-05): Atopic Dermatitis (Eczema)
- [ARQ-234](https://sec-api.dev/pdufa/arq-234): moderate-to-severe atopic dermatitis
- [ZORYVE (roflumilast)](https://sec-api.dev/pdufa/roflumilast): seborrheic dermatitis in individuals aged 9 years and older, with no limitation, plaque psoriasis in children down, infants with atopic dermatitis down, plaque psoriasis, vitiligo and decision, vitiligo and share its decision
- [Roflumilast cream 0.3%](https://sec-api.dev/pdufa/roflumilast-cream-0-3): Atopic Dermatitis

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/arqt/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "ARQT catalysts: Arcutis Biotherapeutics, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/arqt/catalysts

```bibtex
@misc{secapidev_companies_arqt_catalysts_20261116,
  title        = {ARQT catalysts: Arcutis Biotherapeutics, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/arqt/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_arqt_catalysts_20261116","title":"ARQT catalysts: Arcutis Biotherapeutics, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/arqt/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
